Hemangiomas: Types, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Hemangiomas are the most common benign vascular tumors, arising from proliferation of endothelial cells. They are classified by clinical behavior into infantile hemangiomas (IH) — the most common type, GLUT-1 positive — and congenital hemangiomas (rapidly involuting, RICH; non-involuting, NICH; partially involuting, PICH), which are GLUT-1 negative and fully formed at birth. Infantile hemangiomas affect approximately 4–5% of infants, with higher prevalence in premature infants (up to 10%), white infants, and females (female:male ratio 3–5:1). IH are absent or barely visible at birth, proliferate rapidly during the first 3–6 months of life, and then slowly involute over 3–7 years. By age 5, 50% have involuted; by age 7, 70–80% have involuted. Hepatic hemangiomas — the most common benign liver tumor in adults — are distinct incidental lesions managed conservatively. Giant hepatic hemangiomas (>10 cm) may cause Kasabach-Merritt phenomenon — consumptive coagulopathy with life-threatening thrombocytopenia — in neonates with kaposiform hemangioendothelioma (a distinct lesion).

The pathogenesis of infantile hemangiomas involves aberrant vasculogenesis from hemangioma stem cells (HemSCs) with upregulated VEGF, FGF, and HIF-1α signaling. Risk factors for IH include prematurity (particularly gestational age <32 weeks), low birth weight (<1500g), fair skin, female sex, multiple gestation pregnancy, advanced maternal age, placenta previa, pre-eclampsia, and chorionic villus sampling. The exact trigger for post-natal hemangioma growth is unknown but hypoxia may play a role. A familial predisposition is recognized, though no specific genetic mutations have been consistently identified for sporadic IH. Hepatic hemangiomas in adults are congenital vascular malformations rather than true neoplasms; female sex hormones may promote their growth, explaining the association with oral contraceptive use and pregnancy.

Infantile hemangiomas typically appear at 2–4 weeks of age as a small red patch or telangiectatic macule. Superficial hemangiomas are bright red, raised, strawberry-like lesions. Deep hemangiomas manifest as bluish, compressible subcutaneous swellings with or without overlying telangiectasia. Mixed hemangiomas have both superficial and deep components. Growth is rapid in the first 3–6 months, then slows. Most are uncomplicated — located on the skin, growing predictably, and involuting without sequelae. However, in approximately 10–15% of cases, complications arise requiring treatment: ulceration (most common complication, 15–25% of treatment-requiring IH), functional impairment (periocular IH causing amblyopia or astigmatism, airway IH causing stridor), disfigurement (nasal tip 'Cyrano' hemangioma, lip), or life-threatening complications (hepatic IH causing congestive heart failure, high-output cardiac failure, hypothyroidism from over-expression of type 3 iodothyronine deiodinase). PHACE syndrome — Posterior fossa malformations, Hemangioma, Arterial anomalies, Cardiac defects, Eye anomalies — complicates large facial segmental IH.

Most IH are diagnosed clinically based on characteristic appearance and growth trajectory. GLUT-1 immunostaining of biopsy tissue confirms IH vs vascular malformations when diagnosis is uncertain. Doppler ultrasound is the first-line imaging modality for hemangiomas, demonstrating high flow in proliferating lesions. MRI with gadolinium enhancement is preferred for deep or visceral hemangiomas, hepatic lesions, and PHACE syndrome evaluation (brain/neck MRI/MRA required for facial segmental IH). Thyroid function tests (TSH, T4) are required for infants with diffuse hepatic IH. Echocardiography is indicated for large hepatic IH to assess cardiac function and detect high-output heart failure. Cardiac and ophthalmologic evaluation is required in PHACE syndrome. Brain MRI is indicated for lumbosacral/perineal IH to exclude spinal dysraphism (LUMBAR syndrome: Lower body hemangioma, Urogenital anomalies, Myelopathy, Bony deformities, Anorectal anomalies, Renal anomalies).

Most infantile hemangiomas (80–90%) require no treatment and are managed expectantly with photographic monitoring. Treatment is indicated for ulcerated, functional, life-threatening, or cosmetically significant lesions. Oral propranolol — a non-selective beta-blocker — is the first-line treatment for IH requiring systemic therapy (FDA-approved, 2014), typically given at 1–3 mg/kg/day for 6 months starting after 5 weeks of corrected gestational age. Propranolol achieves complete or near-complete involution in 85–95% of treated lesions by inducing vasoconstriction, reducing VEGF expression, and promoting hemangioma stem cell apoptosis. Pre-treatment cardiology evaluation is required in PHACE syndrome due to risk of stroke from head and neck arterial anomalies. Timolol 0.5% gel (topical beta-blocker) is effective for small superficial lesions. Pulsed-dye laser (585–595 nm) treats residual telangiectasia and ulceration. Surgical excision is reserved for pedunculated lesions, involuted hemangiomas with significant residual skin changes, and nasal tip hemangiomas. Hepatic IH causing hypothyroidism require high-dose levothyroxine; those causing cardiac failure may require propranolol, embolization, or liver transplant.

The prognosis for infantile hemangiomas is excellent. Without treatment, 80–90% involute spontaneously by age 5–7 years — by age 5, approximately 50% have fully involuted; by age 7, 70–80% have resolved. However, involuted hemangiomas may leave residual skin changes — telangiectasia, fibrofatty tissue, or atrophic scarring — in approximately 50% of cases, which may require pulsed-dye laser treatment or surgical correction for cosmetic improvement. With propranolol treatment, near-complete involution is achieved in 85–95% of treated infantile hemangiomas, with minimal residual changes. Periocular hemangiomas managed appropriately do not cause permanent visual impairment in most cases when amblyopia treatment is initiated promptly. Hepatic hemangiomas in adults have an excellent prognosis — the vast majority remain stable throughout life, and the risk of spontaneous rupture or malignant transformation is negligible; observation alone is appropriate for most lesions. Life-threatening complications (cardiac failure, hypothyroidism from massive hepatic IH in neonates) are managed effectively with propranolol, embolization, or thyroid hormone replacement. PHACE syndrome patients require long-term monitoring for associated arterial anomalies, cardiac defects, and ophthalmological sequelae. Functional complications such as deprivational amblyopia from periocular hemangioma require early aggressive treatment to ensure normal visual development, with good outcomes if intervention is timely.

No evidence-based strategies prevent infantile hemangioma formation. Avoidance of iatrogenic prematurity — through maternal progesterone supplementation and cerclage in at-risk pregnancies — may reduce IH risk by preventing preterm birth, though this is not a standard indication. Hepatic hemangiomas in adults do not require preventive measures, but women with known large hepatic hemangiomas should discuss the risk of growth with estrogen-containing medications before prescribing combined oral contraceptive pills or hormone replacement therapy. Avoidance of trauma to large hemangiomas prevents ulceration during the proliferative phase.

Immediate evaluation is required for: stridor in an infant with a facial or subglottic hemangioma (airway emergency); rapidly growing periocular hemangioma threatening the visual axis (risk of deprivational amblyopia — ophthalmology referral within 48 hours); large hepatic hemangioma in a neonate causing congestive heart failure, respiratory distress, or abdominal compartment syndrome; and ulcerated hemangioma with active bleeding or signs of secondary infection. All infants with large facial segmental hemangiomas (covering one of five facial segments) should have MRI brain/neck with angiography performed to screen for PHACE syndrome before starting propranolol due to risk of drug-induced cerebral ischemia in arterial anomalies. Adult hepatic hemangiomas discovered incidentally with typical MRI features require no intervention — reassure and discharge, unless the lesion is >10 cm, growing rapidly, or symptomatic.